戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 therapeutic potential for prevention of this blinding disease.
2 identify novel targets for treatment of this blinding disease.
3 argeted for therapeutic intervention in this blinding disease.
4 plications of the racial disparities of this blinding disease.
5 ve and therapeutic strategy for this common, blinding disease.
6 fic therapeutic targets in treatment of this blinding disease.
7 f autosomal dominant retinitis pigmentosa, a blinding disease.
8 have the potential to treat this devastating blinding disease.
9 in-3 signaling can be targeted to treat this blinding disease.
10 nd non-African ancestry populations for this blinding disease.
11  century, childhood glaucoma was a uniformly blinding disease.
12 ated macular degeneration, which is a common blinding disease.
13  photoswitches to restore visual function in blinding disease.
14      Primary open-angle glaucoma (POAG) is a blinding disease.
15 erapeutic candidates for the mutation-caused blinding disease.
16 (LCA1), an autosomal recessive human retinal blinding disease.
17  is necessary to achieve elimination of this blinding disease.
18  reinfection, known risk factors which drive blinding disease.
19 Paget disease of bone, and glaucoma, a major blinding disease.
20 PE), the two layers that are damaged in this blinding disease.
21 to the most common form of glaucoma, a major blinding disease.
22  support neuroprotective strategies for this blinding disease.
23 d and targeted treatments to ameliorate this blinding disease.
24 bute to the development of glaucoma, a major blinding disease.
25 ibute to photoreceptor degeneration in these blinding diseases.
26 merged as a potential treatment approach for blinding diseases.
27 ased opsins can enhance vision in late-stage blinding diseases.
28 on, and their degeneration underlies several blinding diseases.
29 on restoration in patients with degenerative blinding diseases.
30 increases the risk of developing potentially blinding diseases.
31 sent in food exhibit advantageous effects in blinding diseases.
32 ent of miRNA-targeted therapeutics to combat blinding diseases.
33 ions, or aging is the principal pathology of blinding diseases.
34  poor visual acuity were less aware of these blinding diseases.
35 sual cycle defects and consequently mitigate blinding diseases.
36  implicated as causes of or risk factors for blinding diseases.
37 hysiological vascular development and common blinding diseases.
38 late-stage intervention in the management of blinding diseases.
39 lerate the development of new treatments for blinding diseases.
40 r restoring retinal function in degenerative blinding diseases.
41 ssociated disorders, including several human blinding diseases.
42 ially promising agents for the fight against blinding diseases.
43 of its regression in humans leads to several blinding diseases.
44 n and expand their indications to many other blinding diseases.
45 s the basis for vision loss in several major blinding diseases.
46  severe vision impairment for many prevalent blinding diseases.
47             Of the 6.1 million patients with blinding diseases, 37 189 who received ranibizumab, 39 4
48  Retinitis pigmentosa (RP) is a debilitating blinding disease affecting over 1.5 million people world
49 octurnal hemoglobinuria (PNH), to the common blinding disease age-related macular degeneration (AMD).
50 acranial hypertension (IIH) is a potentially blinding disease and may require surgical management whe
51  macular degeneration (AMD) is a progressive blinding disease and represents the leading cause of vis
52  vitreoretinopathy (PVR) is a nonneovascular blinding disease and the leading cause for failure in su
53 monstrated its therapeutic value in treating blinding diseases and diverse cancer types.
54 nd facilitate global intervention methods in blinding diseases and other neurodegenerative disorders.
55 validate the use of the macaque for modeling blinding disease, and provide a foundation for investiga
56 y congenital glaucoma (PCG) is a potentially blinding disease, and the search for the best surgical o
57 receptor loss results in vision loss in many blinding diseases, and metabolic dysfunction underlies p
58 ons (IPDs), a group of incurable progressive blinding diseases, are caused by mutations in more than
59 degeneration, retinitis pigmentosa and other blinding diseases, as well as the ROI-induced death of o
60   Proliferative vitreoretinopathy (PVR) is a blinding disease associated with rhegmatogenous retinal
61     This might open new treatment options in blinding diseases associated with corneal edema and tran
62 Twelve percent of American patients with the blinding disease autosomal dominant retinitis pigmentosa
63 r cells, are a major cause of the hereditary-blinding disease, autosomal dominant retinitis pigmentos
64 ne of the most prevalent causes of the human blinding disease, autosomal dominant retinitis pigmentos
65  retinopathy is the most common irreversible blinding disease but its pathophysiology is not complete
66 of WHO's strategy to eliminate trachoma as a blinding disease by 2020.
67 he human RPE65 gene cause a severe recessive blinding disease called Leber's congenital amaurosis.
68 the gene encoding this protein can lead to a blinding disease called retinitis pigmentosa, which is i
69 Rhodopsin mislocalization is associated with blinding diseases called retinal ciliopathies.
70 ng them, 99 % were aware that diabetes was a blinding disease caused by DR.11.5 % of the subjects wer
71  of recessive Stargardt macular dystrophy, a blinding disease caused by dysfunction or loss of the AB
72 ive Stargardt maculopathy is another central blinding disease caused by mutations in the gene for ABC
73               Retinitis pigmentosa (RP) is a blinding disease caused by photoreceptor degeneration, d
74 itis pigmentosa (RP) is a group of inherited blinding diseases caused by mutations in multiple genes
75  mutant recapitulated many features of human blinding diseases caused by RLBP1 mutations and provided
76 the basis for an effective strategy to treat blinding diseases caused by RPE dysfunction.
77  macular degeneration (AMD) are degenerative blinding diseases caused by the death of rods and cones,
78 d age-related macular degeneration (AMD) are blinding diseases caused by the degeneration of rods and
79 l corneal dystrophy (FECD) is a progressive, blinding disease characterized by corneal endothelial (C
80  neuropathy (LHON) is a maternally inherited blinding disease characterized by degeneration of retina
81                    Glaucoma is a progressive blinding disease characterized by gradual loss of vision
82                         Glaucoma is a common blinding disease characterized by loss of retinal gangli
83    Retinitis pigmentosa (RP) is an inherited blinding disease characterized by progressive loss of re
84 in are two genes linked to glaucoma, a major blinding disease characterized by progressive loss of re
85   Importance: HSK in humans is a potentially blinding disease characterized by recurrent inflammation
86  degeneration (AMD) is a common, potentially blinding disease characterized by the presence of extrac
87  lead to a spectrum of currently untreatable blinding diseases collectively termed retinitis pigmento
88 hly intravitreal anti-VEGF medications for a blinding disease (diabetic retinopathy, diabetic macular
89                  Dominant optic atrophy is a blinding disease due to the degeneration of the retinal
90 ged cause of retinal degeneration in genetic blinding diseases (e.g., Stargardt) and a possible etiol
91 ment epithelium (RPE) 65 are associated with blinding diseases, for which there is no effective thera
92 in each of these tissues are associated with blinding diseases-for example, glaucoma (ONH and PPS), o
93 erity from minor transient discomfort to the blinding disease herpes stromal keratitis, yet most pati
94 tric glaucoma providers managing potentially blinding disease in children.
95 cular degeneration (AMD) is a multifactorial blinding disease in the elderly.
96 acular degeneration (AMD) is the most common blinding disease in those over 60 years.
97                Glaucoma is a multi-factorial blinding disease in which genetic factors play an import
98 are associated with a spectrum of congenital blinding diseases in humans.
99 cific cells in the outer retina for treating blinding diseases in patients.
100 RPE) gene RPE65 are associated with multiple blinding diseases including Leber's Congenital Amaurosis
101                             Many untreatable blinding diseases involve degeneration of retinal pigmen
102 human diseases, ranging from the devastating blinding disease Leber congenital amaurosis (LCA) to Sen
103  single amino acid mutation occurring in the blinding disease, Leber's hereditary optic neuropathy (L
104                                     In these blinding diseases, macrophages accumulate at atrophic si
105                           PTC, a potentially blinding disease, most commonly manifests with headache
106 gardt's macular degeneration is an inherited blinding disease of children caused by mutations in the
107 essive Stargardt's macular degeneration is a blinding disease of children caused by mutations in the
108    Mutations in the human RPE65 gene cause a blinding disease of infancy called Leber congenital amau
109 ge-related macular degeneration, a prevalent blinding disease of the elderly, is strongly associated
110 cular degeneration (AMD) is a common central blinding disease of the elderly.
111 related macular degeneration (AMD), a common blinding disease of the elderly.
112 nal ganglion cells is the final end point in blinding diseases of the optic nerve such as glaucoma.
113 e-editing tool and could enable treatment of blinding diseases of the retina.
114               Retinitis pigmentosa (RP) is a blinding disease often associated with mutations in rhod
115 r preventing the loss of vision because most blinding diseases originate in cellular components of th
116 the retina and is a major feature of leading blinding diseases, particularly diabetic retinopathy.
117 bility, and enables the dissection of common blinding disease phenotypes.
118 Retinitis pigmentosa is a heritable group of blinding diseases resulting from loss of photoreceptors,
119 the economic and social consequences of this blinding disease rise.
120                  The use of gene therapy for blinding disease shows growing promise; however, due to
121 ents that have the potential to treat common blinding diseases such as age-related macular degenerati
122 play a role in retinal damage in a number of blinding diseases such as glaucoma and diabetic retinopa
123  dysfunctional autophagy could contribute to blinding diseases such as macular degeneration.
124 al of pathologic angiogenesis that occurs in blinding diseases such as proliferative diabetic retinop
125  of retinal degeneration in animal models of blinding diseases such as retinitis pigmentosa (RP) and
126 eptor cells could be a general treatment for blinding diseases such as retinitis pigmentosa.
127 s, including certain cancers and potentially blinding diseases, such as age-related macular degenerat
128 e understanding of the molecular pathways of blinding diseases, such as diabetic retinopathy and glau
129               Retinitis Pigmentosa (RP) is a blinding disease that arises from loss of rods and subse
130 tricial and, owing to trichiasis, eventually blinding disease that supervenes in some individuals lat
131 rosis (LCA) encompasses a set of early-onset blinding diseases that are characterized by vision loss,
132  in patients with STGD1 as well as for other blinding diseases that require the delivery of large gen
133 one-rod homeobox (CRX) are linked with human blinding diseases that vary in their severity and age of
134 s a broad-spectrum therapeutic treatment for blinding diseases, the target cells of exogenous CNTF an
135  for sexually transmitted infections and the blinding disease trachoma, which affect hundreds of mill
136 uses sexually transmitted infections and the blinding disease trachoma.
137 Leber's congenital amaurosis (LCA) is a rare blinding disease, usually inherited in an autosomally re
138 advance our understanding of the etiology of blinding diseases, we used single-cell RNA-sequencing (s
139 rophy/malattia leventinese (DHRD/ML), a rare blinding disease with clinical pathology similar to age-
140 eber congenital amaurosis (LCA), a childhood blinding disease with early-onset retinal degeneration a
141       Retinitis pigmentosa (RP) is a genetic blinding disease with over 80 causative genes.
142 ng protein-like1 (AIPL1) are associated with blinding diseases with a wide range of severity in human
143 ital amaurosis (LCA) is a group of inherited blinding diseases with onset during childhood.
144 mal vessels is critical to controlling these blinding diseases with targeted therapy.
145 genesis or failure of treatment of all major blinding diseases, with postoperative wound healing resp
146  Fibrosis-related events play a part in most blinding diseases worldwide.
147  the complement system is a feature of these blinding diseases, yet how the RPE combats complement at

 
Page Top